Univariable Cox proportional hazard analysis of factors related to loss of clinical benefit after TNFi discontinuation (n=325) while in LDA
| Characteristic at discontinuation | Univariable HR (95% CI) | p Value |
|---|---|---|
| Age (<53 years (ref)) | 0.74 (0.54 to 1.04) | 0.086 |
| Gender (male (ref)) | 1.02 (0.74 to 1.42) | 0.879 |
| Smoker (never (reference)) | ||
| Former | 1 (0.67 to 1.48) | |
| Current | 1.78 (1.167 to 2.65) | 0.027 |
| BMI (overweight vs normal (ref)) | 0.85 (0.57 to 1.27) | 0.428 |
| Duration of PsA (>1 vs ≤1 year (ref)) | 0.83 (0.44 to 1.58) | 0.575 |
| CDAI (<3.2 (ref) vs ≥3.2) | 1.43 (1.03 to 2.00) | 0.032 |
| TJC (0 (ref) vs >0) | 1.32 (0.95 to 1.85) | 0.095 |
| SJC (0 (ref) vs >0) | 0.83 (0.55 to 1.24) | 0.367 |
| Patient global assessment (<5 (ref) vs ≥5 ref) | 1.70 (1.16 to 2.51) | 0.007 |
| Physician global assessment (<15 (ref) vs ≥15) | 1.13 (8.82 to 1.58) | 0.454 |
| mHAQ (0 (ref) vs >0 ref) | 0.85 (0.61 to 1.18) | 0.338 |
| mDAS (moderate vs low) | 1.65 (1.09 to 2.49) | 0.012 |
Factors that were significant at the 20% level (p value <0.20) were further evaluated in a multivariable analysis model, although no new differences arose.
BMI, body mass index; CDAI, clinical disease activity index; LDA, low disease activity; mDAS, modified disease activity score; mHAQ, modified health assessment questionnaire; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.